So if retatrutides phase 3 trials finish in 2025 or early 2026, approval and market availability by late 2026 or 2027 is a plausible target assuming all goes well
PlexusDx's Precision Peptide Genetic Test ($298) identifies predispositions in GLP-1 pathway genes (GIPR, FTO, MC4R)
This flexibility ensures that nothing stands in the way of your weight loss journey
Sienes Bailo P, Llorente Martn E, Calmarza P, Montolio Breva S, Bravo Gmez A, Pozo Girldez A, et al
It may be that indirect effects such as the rapid weight loss, hormonal changes, and nutritional deficiencies linked to these medications affect your hair health
The FDA recommends talking with your healthcare provider before considering them